BioSpace News Archive

FDA

FDA Review: Tenaya, GSK, Pfizer and More

Although it was a short week due to the Labor Day holiday, the FDA maintained a steady pace of business.

September 9, 2022
·
2 min read
·
Alex Keown
Business

Phase III Data in Hand, Sanofi-Regeneron’s Dupixent Targets Another Approval

Sanofi and Regeneron presented results from the Phase III PRIME trial that showed Dupixent strongly improves itching and skin lesions in adult patients with prurigo nodularis.

September 9, 2022
·
2 min read
·
Tristan Manalac
Research Roundup: a New Treatment Target for Down Syndrome and More

Researchers have discovered a potential treatment target for Down syndrome, Th17 cells could mitigate microbiome-linked diseases and electroacupuncture in Parkinson’s disease.

September 9, 2022
·
4 min read
·
Katherine Davis
With 34 Vaccine Programs in Development, Moderna Eyes Global Launches

Moderna is preparing for multiple product launches over the next several years, including RSV and flu vaccines and boosters for COVID-19. It is also aiming mRNA programs at rare diseases.

September 9, 2022
·
4 min read
·
Alex Keown
Career Advice

The Best Life Science Careers for the Future of the Industry

As automation ramps up in the coming years, many jobs will be lost to machines. Here are a few life science sectors that are expected to maintain steady growth in the coming years.

September 9, 2022
·
3 min read
·
Franklin Carpenter
Business

Cluster-busters against Cancer and a Potential New Gene Therapy for LCA

TumorGen and PhenoVista are partnering to explore metastatic cancer cell clusters, while NIH has developed a potential new gene therapy approach for Leber congenital amaurosis.

September 9, 2022
·
3 min read
·
Alex Keown
Drug Development

Biogen’s Antibody Lupus Treatment Shows Mid-Stage Promise

Biogen announced that its mid-stage monoclonal antibody litifilimab is showing promise in reducing joint pain related to systemic lupus erythematosus (SLE) lupus.

September 9, 2022
·
3 min read
·
Alex Keown
Drug Development

ESMO 2022: AstraZeneca, BioNTech, Adaptimmune and Immunocore Share Data

An AstraZeneca/Merck combination showed mostly positive ovarian cancer data, Adaptimmune posted a strong ORR in solid tumors and BioNTech revealed data from a CAR-T cell therapy.

September 9, 2022
·
5 min read
·
Alex Keown
Drug Development

A Post-mortem on the Failed Nektar-BMS Partnership at ESMO

The ESMO conference is serving as a post-mortem on the trials that sunk the multi-billion-dollar partnership between Bristol-Myers Squibb and Nektar Therapeutics.

September 9, 2022
·
1 min read
·
Paul Elias
Antengene to Present at Upcoming Industry Conferences - September 09, 2022

Antengene Corporation Limited announced that members of the senior management team will participate and present at the following industry conferences in the U.S. in September.

September 9, 2022
·
2 min read